TP53 and lung adenocarcinoma: As shown in Table S1, the lung adenocarcinoma patients’ clinical characteristics including TNM stage, pathologic stage, primary therapy outcome, gender, race, anatomic neoplasm subdivision, smoking history, TP53, and KRAS status were gathered.